…survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial Presenting author: Sophie Piperno-Neumann Session: Mini oral session…

…treatment options in order to be active participants in treatment and care. AIM at Melanoma’s global research initiatives include The…

…genetics with the patient’s age and clinical features of the melanoma to assess whether a patient has a low or…

…recognizing Merlin CP-GEP¹ (clinicopathologic–gene expression profile test) as the first and only molecular test that may be used in select early-stage melanoma patients.…

…Their large family keeps them happy and on the move! Bob is actively involved in AIM at Melanoma and other…

An exciting new development in melanoma treatment is the recent FDA-approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of…

How much is enough? Exploring excisional margins for in situ melanoma When a patient with melanoma in situ has a…

…everyone affected by melanoma.  DONATE TODAY!  Stay Informed: Access the latest research and treatment options that enhance the fight against…

In 2016, the late Valerie Guild—founder and then-president of AIM at Melanoma—attended a melanoma conference and noticed something striking: While…

AIM at Melanoma is pleased to announce Peer Connect, a peer-to-peer mentoring program for anyone touched by melanoma. Here’s how…